Market Newsdesk

Investortools Adds ICE’s Streaming Evaluated Bond Prices to the Investortools Dealer Network in Perform

Includes access to ICE’s Liquidity Indicators^™ and Best Execution services

ATLANTA & NEW YORK–(BUSINESS WIRE)–
Intercontinental Exchange, Inc. (NYSE: ICE), a leading global provider of data, technology, and market infrastructure, today announced that its streaming Continuous Evaluated Pricing (CEP^™) for fixed income securities will now be available on the Investortool’s Dealer Network (IDN) in Perform, offering institutional investors and private wealth managers streaming evaluations and related trading analytics to help drive trading strategies and investment decision-making.

ICE’s CEP provides front, middle and back-office professionals with streaming intraday evaluations for U.S. Municipal, Corporate, emerging market and sovereign bonds, as well as agencies, TBA Mortgages, MBS Pass-throughs and Money Market securities. CEP offers greater pre-trade transparency, which supports price discovery and idea generation.

“Increased price volatility in bond markets has been a valuable reminder about the importance of providing more transparency into the markets we serve,” said Jon Anderson, Chief Product Officer and Co-Head at Investortools. “ICE’s streaming pre-trade prices will make it easier for our clients to quickly discover opportunities in the market and achieve a low touch, electronic trading workflow.”

As part of this agreement, Investortools also plans to add access to additional fixed income trading analytics from ICE, including:

• Continuous Market Depth Indicators (CDMI) – provides perspective on the number of sources quoting a security as well as the number of trades executed on the security.
• Market Sentiment Scores – intended to help clients identify when there may be greater dislocation and differences of opinion in the market as to what an asset’s value may be.
• ICE Liquidity Indicators – provides an independent, near-term view of relative liquidity, including the ability to exit a position at or near the current value.
• Best Execution& TCA – for measuring bond trade execution quality and trading effectiveness across a growing number of venues and protocols.

“Fixed income markets have traditionally been more opaque with wider spreads than other asset classes,” said Amanda Hindlian, President of Fixed Income and Data Services at ICE. “With ICE’s CEP, we’re now able to offer companies like Investortools and their customers intra-day streaming evaluations for a much broader universe of fixed income securities. When paired with our analytics, investors and traders have a powerful tool for evaluating securities and portfolios and making trading decisions.”

The addition of ICE’s data and analytics on Perform builds on the two companies’ prior integration to the ICE Bonds execution platforms on the Investortools Dealer Network. This connectivity gives Investortools’ customers access to ICE Bonds’ deep liquidity pools for Municipal Bonds via trading protocols including click-to-trade, portfolio trading and request for quote. ICE Bonds also provides markets for Corporates, Treasuries, Agencies and Certificates of Deposit.

“Pairing Perform’s analytics with ICE’s streaming evaluations and ICE Bonds’ deep liquidity pools gives users of the IDN a truly unique opportunity to manage their risk management and trading needs,” said Peter Borstelmann, President of ICE Bonds. “We’re excited to work with Investortools to launch this next stage of connectivity.”

Perform offers end-to-end portfolio management including trade allocation, compliance, trade messaging and performance attribution to global institutional and private wealth managers. Customers also operate in a straight-through-processing environment, with Perform providing pre-trade analytics and compliance, and trading through ICE’s Bond’s execution platform.

For more information about ICE Bonds, please visit: https://www.theice.com/fixed-income/ice-bonds.

About Investortools, Inc.

With 40 years of experience, Investortools specializes in portfolio and order management and credit analysis systems for institutional investors, including many of the largest asset managers, mutual funds, banks, insurance companies, securities dealers, advisers, rating agencies and financial organizations. Headquartered in Colorado Springs, Investortools and its affiliates have offices in the U.S., Europe, and Asia. For more information, please visit https://www.invtools.com.

About Intercontinental Exchange

Intercontinental Exchange, Inc. (NYSE: ICE) is a Fortune 500 company that designs, builds and operates digital networks to connect people to opportunity. We provide financial technology and data services across major asset classes that offer our customers access to mission-critical workflow tools that increase transparency and operational efficiencies. We operate exchanges, including the New York Stock Exchange, and clearing houses that help people invest, raise capital and manage risk across multiple asset classes. Our comprehensive fixed income data services and execution capabilities provide information, analytics and platforms that help our customers capitalize on opportunities and operate more efficiently. At ICE Mortgage Technology, we are transforming and digitizing the U.S. residential mortgage process, from consumer engagement through loan registration. Together, we transform, streamline and automate industries to connect our customers to opportunity.

Trademarks of ICE and/or its affiliates include Intercontinental Exchange, ICE, ICE block design, NYSE and New York Stock Exchange. Information regarding additional trademarks and intellectual property rights of Intercontinental Exchange, Inc. and/or its affiliates is located here. Key Information Documents for certain products covered by the EU Packaged Retail and Insurance-based Investment Products Regulation can be accessed on the relevant exchange website under the heading “Key Information Documents (KIDS).”

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 — Statements in this press release regarding ICE’s business that are not historical facts are “forward-looking statements” that involve risks and uncertainties. For a discussion of additional risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see ICE’s Securities and Exchange Commission (SEC) filings, including, but not limited to, the risk factors in ICE’s Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the SEC on February 2, 2023.

About ICE Bonds

Trading and execution services are offered through ICE Bonds Securities Corporation or ICE Bonds member FINRA, MSRB and SIPC. The information found herein, has been prepared solely for informational purposes and should not be considered investment advice, is neither an offer to sell nor a solicitation of an offer to buy any financial product(s), is intended for institutional investors only and is not intended for retail customer use.

Category: Fixed Income and Data Services

SOURCE: Intercontinental Exchange

ICE-CORP

View source version on businesswire.com: https://www.businesswire.com/news/home/20230524005223/en/

ICE Media Contact:

Damon Leavell

+1 212 323 8587

[email protected]

[email protected]

ICE Investor Relations Contact:

Katia Gonzalez

+1 678 981 3882

[email protected]

[email protected]

To learn more about Investortools software and the Investortools Dealer Network, please contact:

James Morris

Senior Vice President

[email protected]

+1 630 466 6465

Investortools Media Contact:

Jessica McDaniel

Marketing Lead

[email protected]

+1 719 621 6364

KEYWORDS: United States North America New York Georgia

INDUSTRY KEYWORDS: Banking Personal Finance Professional Services Finance

MEDIA:

Logo

Vistagen Awarded Mental Health America’s Platinum Bell Seal for Workplace Mental Health

Mental Health America’s prestigious national certification complements Vistagen’s ongoing efforts to improve mental health care across the U.S.

Timely recognition comes during Mental Health Awareness Month and MHA’s nationwide efforts to fight stigma and provide support around mental health

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that it has been recognized by Mental Health America (MHA) for its commitment to fostering mental health and well-being in the workplace. Vistagen’s supportive workplace culture, mental health care benefits, focus on inclusion, and wellness programs have earned it MHA’s Platinum Bell Seal for Workplace Mental Health, MHA’s highest award for comprehensive workplace mental health support.

“Our commitment to improving the trajectory of global mental health starts in our own company,” said Shawn Singh, Chief Executive Officer of Vistagen. “As we strive to develop transformative medicines for patients suffering from anxiety, depression and other mental health disorders, we prioritize supporting our employees’ mental health and well-being, both inside and outside of our workplace. May is Mental Health Awareness Month, an important time each year to elevate important issues involving mental health and encourage further progress in discussing, recognizing, and treating mental health disorders. We thank Mental Health America for acknowledging our commitment to our team’s mental health, an essential factor in our team’s ability to remain laser-focused on achieving our mission.”

MHA’s Platinum Bell Seal certification, and Vistagen’s ongoing development of innovative mental health medicines, come as the United States grapples with a mental health epidemic exacerbated by pandemic-related isolation, as well as a new advisory from the U.S. Surgeon General on the disastrous mental health outcomes associated with social isolation and loneliness. Vistagen’s leading-edge workplace mental health policies and programs aim to give its employees the time and resources they need to care for their mental health and foster a positive workplace culture through team building, flexible work arrangements, and a commitment to diversity and inclusion.

About MHA’s Bell Seal for Workplace Mental Health

The Bell Seal for Workplace Mental Health national certification program recognizes employers committed to creating mentally healthy workplaces. Led by MHA’s rich history in research and advocacy, the Bell Seal’s holistic evaluation of employer practices considers the entire employee experience. In collaboration with the U.S. Department of Labor, U.S. Centers for Disease Control and Prevention and national companies, MHA is committed to furthering worker safety, health, and well-being alongside leading health and advocacy organizations. Bell Seal recognition builds a sense of pride in employers and optimism in existing and prospective employees alike. Qualifying organizations are recognized at different levels – bronze, silver, gold or platinum – and are assessed based on how mental health is approached via four categories: workplace culture, benefits, compliance and wellness programs.

About Vistagen

Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are currently available for treatment of anxiety, depression and multiple CNS disorders. Vistagen’s pipeline includes six product candidates, including five clinical-stage investigational agents belonging to a new class of drugs known as pherines, in addition to AV-101, an oral antagonist of the glycine site of the N-methyl-D-aspartate receptor (NMDAR). Pherines, which are administered as nasal sprays, are designed with an innovative rapid-onset mechanism of action that activates chemosensory neurons in the nasal passages and can selectively and beneficially impact key neural circuits in the brain without requiring systemic uptake or direct activity on CNS neurons. Vistagen’s AV-101 inhibits activity of the ion channel of the NMDAR but does not block it. Vistagen is passionate about transforming mental health care and redefining what is possible in the treatment of anxiety, depression and several other CNS disorders. Connect at www.Vistagen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230524005380/en/

Media:

Nate Hitchings

SKDK

[email protected]

Investors:

Mark McPartland

Senior Vice President, Investor Relations

(650) 577-3606

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Mental Health Health General Health Research Pharmaceutical Science

MEDIA:

Logo

Surgeons Successfully Complete First Surgical Cases Using Stryker’s Q Guidance System with Cranial Guidance Software

Technology provides groundbreaking planning and guidance capabilities

LEESBURG, Va.–(BUSINESS WIRE)–Stryker (NYSE:SYK), one of the world’s leading medical technology companies, announced that Early Product Surveillance (EPS) cases utilizing its Q Guidance System with Cranial Guidance Software are underway. The technology provides surgeons with image-based planning and an intraoperative guidance system designed to support cranial surgeries.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230524005371/en/

“In my opinion, Stryker’s Q Guidance System with Cranial Guidance Software could be the new gold standard for image-guided neurosurgical navigation,” said Dr. Melvin Field, medical director for the Minimally Invasive Brain Surgery program at AdventHealth, and member of Orlando Neurosurgery, one of the first surgeons to bring the system to his OR. “Cranial procedures are extremely delicate, and outcomes may go beyond physical health, potentially altering your patient’s appearance or personality. The system offers advanced planning and guidance capabilities, giving me greater confidence to perform these complex surgeries.”

Leading up to a full commercial launch, Stryker’s Q Guidance System with Cranial Guidance Software will be utilized at five additional EPS sites: the University of New Mexico, the University of Arkansas, the University of Michigan, Thomas Jefferson University, and Lenox Hill Hospital.

Cranial Guidance Software provides a single solution to track brain biopsy and shunt placement instruments, and includes automatic, algorithmic processing as well as comprehensive segmentation capabilities. The software provides tools enabled by gesture recognition for identifying, marking, and localizing targets and anatomical structures of interest.

Learn more about this new technology at strykeronegiantleap.com.

* Dr. Melvin Field is a paid consultant of Stryker. His statements represent his own opinions based on personal experience and are not necessarily those of Stryker. Individual results may vary.

About Stryker

Stryker is one of the world’s leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Medical and Surgical, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 130 million patients annually.

More information is available at www.stryker.com.

Content ID: QGS-PR-6_34619

View source version on businesswire.com: https://www.businesswire.com/news/home/20230524005371/en/

Sampson Public Relations Group

Andrea Sampson, President

[email protected]

Phone: 562 304 0301

KEYWORDS: Virginia United States North America

INDUSTRY KEYWORDS: Technology Surgery Medical Devices Neurology Health Technology Software Physical Therapy Hardware Health

MEDIA:

Logo

Photo

Stryker’s Q Guidance System with Cranial Guidance Software provides surgeons with image-based planning and an intraoperative guidance system designed to support cranial surgeries. (Photo: Business Wire)

Sidus Space to Participate in the Emerging Growth Conference 58 “Space Symposium” – Exploring the Future of Space and Satellite on June 7^th

CAPE CANAVERAL, Fla.–(BUSINESS WIRE)–
Sidus Space (NASDAQ: SIDU) (the “Company”), a Space and Defense-as-a-Service satellite company focused on mission-critical hardware manufacturing; multi-disciplinary engineering services; satellite design, production, launch planning, mission operations; and in-orbit support, today announced that Carol Craig, Founder & CEO, will participate virtually in the Emerging Growth Conference 58 “Space Symposium” – Exploring the Future of Space and Satellite on June 7, 2023 at 1:10 p.m. ET.

To view a webcast of the presentation, please register here.

To schedule a one-on-one meeting with Sidus Space, please contact KCSA Strategic Communications at [email protected].

About Sidus Space

Sidus Space (NASDAQ: SIDU), located in Cape Canaveral, Florida, operates from a 35,000-square-foot manufacturing, assembly, integration, and testing facility focused on vertically integrated Space-as-a-Service solutions including end-to-end satellite support. The company’s rich heritage includes the design and manufacture of many flight and ground component parts and systems for various space-related customers and programs. Sidus Space has a broad range of Space-As-a-Service offerings including space-rated hardware manufacturing, design engineering, satellite manufacturing and platform development, launch and support services, data analytics services and satellite constellation management.

Sidus Space has a mission of Bringing Space Down to Earth™ and a vision of enabling space flight heritage status for new technologies while delivering data and predictive analytics to domestic and global customers. Any corporation, industry, or vertical can start their journey off-planet with Sidus Space’s rapidly scalable, low-cost satellite services, space-based solutions, and testing alternatives. More than just a “Satellite-as-a-Service” provider, Sidus Space is a trusted Mission Partner–from concept to Low Earth Orbit and beyond. Sidus Space is ISO 9001:2015, AS9100 Rev. D certified, and ITAR registered.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230524005360/en/

Investor Relations

Valter Pinto, Managing Director

KCSA Strategic Communications

[email protected]

(212) 896-1254

Media

Katie Kennedy

Senior Vice President

Gregory FCA

[email protected]

1-610-731-1045

KEYWORDS: Florida United States North America

INDUSTRY KEYWORDS: Other Manufacturing Mobile/Wireless Technology Engineering Satellite Telecommunications Aerospace Manufacturing Internet Data Management

MEDIA:

Logo

Medical Properties Trust Announces Closing of Sale of Seven Australian Hospitals

BIRMINGHAM, Ala.–(BUSINESS WIRE)–
Medical Properties Trust, Inc. (the “Company” or “MPT”) (NYSE: MPW) today announced that it has completed, as expected, the sale of seven Australian hospitals for AUD$730 million, with proceeds used to reduce its Australian term loan. MPT additionally settled the pro rata portion of its interest rate swap for a gain of AUD$20 million. The Company expects to close the remaining AUD$470 million in property sales and debt repayment during the current quarter. The 5.7% cap rate implied in the AUD$1.2 billion valuation of MPT’s Australian portfolio provides a strong read-through for similar assets in the Company’s U.S. and Western Europe portfolios.

About Medical Properties Trust, Inc.

Medical Properties Trust, Inc. is a self-advised real estate investment trust formed in 2003 to acquire and develop net-leased hospital facilities. From its inception in Birmingham, Alabama, the Company has grown to become one of the world’s largest owners of hospital real estate with 436 facilities and approximately 44,000 licensed beds in ten countries and across four continents. MPT’s financing model facilitates acquisitions and recapitalizations and allows operators of hospitals to unlock the value of their real estate assets to fund facility improvements, technology upgrades and other investments in operations. For more information, please visit the Company’s website at www.medicalpropertiestrust.com.

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements can generally be identified by the use of forward-looking words such as “may”, “will”, “would”, “could”, “expect”, “intend”, “plan”, “estimate”, “target”, “anticipate”, “believe”, “objectives”, “outlook”, “guidance” or other similar words, and include statements regarding our strategies, objectives, future expansion and development activities, and expected financial performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause our actual results or future events to differ materially from those expressed in or underlying such forward-looking statements, including, but not limited to: (i) the economic, political and social impact of, and uncertainty relating to, potential impact from health crises (like COVID-19); (ii) the ability of our tenants, operators and borrowers to satisfy their obligations under their respective contractual arrangements with us, especially as a result of the adverse economic impact of the COVID-19 pandemic, and government regulation of hospitals and healthcare providers in connection with same (as further detailed in our Current Report on Form 8-K filed with the SEC on April 8, 2020); (iii) our expectations regarding annual guidance for net income and NFFO per share; (iv) our success in implementing our business strategy and our ability to identify, underwrite, finance, consummate and integrate acquisitions and investments; (v) the nature and extent of our current and future competition; (vi) macroeconomic conditions, such as a disruption of or lack of access to the capital markets or movements in currency exchange rates; (vii) our ability to obtain debt financing on attractive terms or at all, which may adversely impact our ability to pursue acquisition and development opportunities and pay down, refinance, restructure or extend our indebtedness as it becomes due; (viii) increases in our borrowing costs as a result of changes in interest rates and other factors; (ix) international, national and local economic, real estate and other market conditions, which may negatively impact, among other things, the financial condition of our tenants, lenders and institutions that hold our cash balances, and may expose us to increased risks of default by these parties; (x) factors affecting the real estate industry generally or the healthcare real estate industry in particular; (xi) our ability to maintain our status as a REIT for federal and state income tax purposes; (xii) federal and state healthcare and other regulatory requirements, as well as those in the foreign jurisdictions where we own properties; (xiii) the value of our real estate assets, which may limit our ability to dispose of assets at attractive prices or obtain or maintain equity or debt financing secured by our properties or on an unsecured basis; (xiv) the ability of our tenants and operators to operate profitably and generate positive cash flow, comply with applicable laws, rules and regulations in the operation of the our properties, to deliver high-quality services, to attract and retain qualified personnel and to attract patients; (xv) potential environmental contingencies and other liabilities; (xvi) the risk that the expected sale of three Connecticut hospitals currently leased to Prospect does not occur; (xvii) the risk that MPT’s expected sale of its Australian portfolio does not occur; (xviii) the risk that other property sales, loan repayments, and other capital recycling transactions do not occur; and (xix) the risks and uncertainties of litigation.

The risks described above are not exhaustive and additional factors could adversely affect our business and financial performance, including the risk factors discussed under the section captioned “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022 and as updated in our quarterly reports on Form 10-Q. Forward-looking statements are inherently uncertain and actual performance or outcomes may vary materially from any forward-looking statements and the assumptions on which those statements are based. Readers are cautioned to not place undue reliance on forward-looking statements as predictions of future events. We disclaim any responsibility to update such forward-looking statements, which speak only as of the date on which they were made.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230523006123/en/

Drew Babin, CFA, CMA

Senior Managing Director – Corporate Communications

Medical Properties Trust, Inc.

(646) 884-9809

[email protected]

KEYWORDS: United States North America Alabama

INDUSTRY KEYWORDS: Health Other Construction & Property Hospitals Commercial Building & Real Estate Construction & Property General Health REIT

MEDIA:

Logo

Thermo Fisher Scientific Hosts 2023 Investor Day

Highlights include the Company’s Industry-Leading Businesses, Trusted Partner Status with Customers and Outstanding Long-Term Financial Outlook

WALTHAM, Mass.–(BUSINESS WIRE)–
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, hosted its 2023 Investor Day today and provided an in-depth review of the Company’s proven growth strategy and its industry-leading businesses: Life Science Solutions, Analytical Instruments, Specialty Diagnostics and Laboratory Products and Biopharma Services.

“Science is advancing at a rapid rate and we continue to bring high-impact innovation, and unique insights to differentiate Thermo Fisher as the trusted partner to our customers,” said Marc N. Casper, chairman, president and chief executive officer. “As an incredibly well-positioned industry leader, we will continue to advance scientific discovery through our Mission to enable our customers to make the world healthier, cleaner and safer.”

Casper continued, “Our proven growth strategy and capital deployment approach, powered by our PPI Business System, create tremendous value for all stakeholders and position the company for a very bright future.”

At today’s event, Thermo Fisher Scientific highlighted:

• Industry leadership in attractive and resilient end markets
  • Thermo Fisher is the leader serving an attractive $240 billion market with long-term market growth of 4% to 6%.

• Leading businesses offer best-in-class products and services
  • Our industry-leading businesses are essential to the work our customers do and enable their success by accelerating their innovation and enhancing their productivity. Our businesses have an outstanding track record of value creation and a bright future.

• Proven growth strategy drives share gain
  • Thermo Fisher’s high-impact innovation, trusted partner status with industry-leading products, services and expertise, and an unparalleled commercial engine continue to uniquely position the company to drive meaningful share gain over the long-term.

• Proven capital deployment approach creates tremendous value
  • Thermo Fisher has a disciplined capital deployment strategy which is a combination of strategic M&A and returning capital to shareholders. Our proven M&A approach leverages rigorous selection criteria, disciplined decision-making and a strong integration process to better serve our customers and create value for our shareholders.

• Practical Process Improvement PPI Business System enables outstanding execution
  • PPI is at the core of Thermo Fisher’s culture, with a focus on continuous improvement that drives quality, productivity and customer allegiance and engages every colleague to find a better way, everyday. PPI delivers competitive advantage, enables successful integration of acquisitions and drives differentiated financial performance.

• Mission-led ESG strategy drives competitive differentiation
  • The company continues to differentiate itself by advancing its ESG strategy including innovating for a cleaner planet, investing in colleagues and communities, and driving impact and accountability. More details can be found in the most recent CSR Report.

• Consistently delivering exceptional financial results with an outstanding long-term outlook
  • Thermo Fisher’s proven growth strategy drives share gain. and its capital deployment approach creates tremendous value, positioning the company to deliver Core organic revenue growth of 7% to 9% and mid-teens adjusted EPS growth over the long-term.

Webcast Replay

To access the presentation materials from today’s investor event, visit the Company’s investor relations website at https://ir.thermofisher.com/investors/news-events/events. A replay will be posted after the event.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Safe Harbor Statement

The following constitutes a “Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements that involve a number of risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: the duration and severity of the COVID-19 pandemic; the need to develop new products and adapt to significant technological change; implementation of strategies for improving growth; general economic conditions and related uncertainties; dependence on customers’ capital spending policies and government funding policies; the effect of economic and political conditions and exchange rate fluctuations on international operations; use and protection of intellectual property; the effect of changes in governmental regulations; any natural disaster, public health crisis or other catastrophic event; and the effect of laws and regulations governing government contracts, as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected. Additional important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in our most recent annual report on Form 10-K and subsequent quarterly report on Form 10-Q, which are on file with the SEC and available in the “Investors” section of our website under the heading “SEC Filings.” While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if estimates change and, therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today.

Use of Non-GAAP Financial Measures

We use certain financial measures not prepared in accordance with generally accepted accounting principles, or GAAP, including adjusted EPS and Core organic revenue growth. These non-GAAP financial measures of Thermo Fisher’s results of operations are not meant to be considered superior to or a substitute for Thermo Fisher’s results of operations prepared in accordance with GAAP. Definitions of these non-GAAP financial measures and, for historical periods, a reconciliation of the non-GAAP financial measures to the most directly comparable GAAP measures is available in the “Investors” section of our website under the heading “Financials.” Thermo Fisher Scientific does not provide GAAP financial measures on a forward-looking basis because we are unable to predict with reasonable certainty and without unreasonable effort items such as the timing and amount of future restructuring actions and acquisition-related charges as well as gains or losses from sales of real estate and businesses, the early retirement of debt and the outcome of legal proceedings. The timing and amount of these items are uncertain and could be material to Thermo Fisher Scientific’s results computed in accordance with GAAP.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230524005343/en/

Media:

Sandy Pound

Phone: 781-622-1223

E-mail: [email protected]

Website: www.thermofisher.com 

Investor:

Rafael Tejada

Phone: 781-622-1356

E-mail: [email protected]

 

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Science Other Science Other Manufacturing Finance Professional Services Technology Manufacturing Other Technology

MEDIA:

Logo

Janus Henderson Global Dividend Index: US Dividend Growth in Q1 Reaches Post-Pandemic Low

• US dividends increased 4.8% on an underlying basis during the first quarter, the slowest rate of growth since the post-pandemic recovery began

• Despite higher interest rates, the US real estate sector was the largest contributor to dividend growth during the quarter

• 97% of US companies raised their dividend payments or held them steady

• Globally, dividends jumped 12.0% on a headline basis to a Q1 record of $326.7bn – boosted by the largest contribution from special dividends in nine years

• Global underlying growth was 3.0%

• Banks, oil producers and vehicle manufacturers were significant drivers of Q1 global growth

DENVER–(BUSINESS WIRE)–
US dividend payments increased 4.8% on an underlying basis during the first quarter of 2023, according to the latest Janus Henderson Global Dividend Index. On a headline basis, which includes special dividends, exchange rate effects and other technical factors, US dividends climbed 8.3% to a record $153.4bn during the quarter. Over a third of the $9.8bn distributed in special dividends in the US came from the booming oil sector, but the largest was distributed by Ford Motor, which used strong free cash flow to fund the one-off payment.

Globally, dividends are off to a strong start to 2023 on the back of booming special dividends. The headline total rose 12.0% to a first-quarter record of $326.7bn. Underlying growth was significantly slower at 3.0%.

One-off special dividends at highest level since 2014

One-off special dividends of $28.8bn globally were the second highest on record (after Q1 2014). Ford and Volkswagen accounted for almost a third of the world’s Q1 special dividends. Headline payouts from the vehicles sector were ten times larger year-on-year as a consequence. One-off special dividends also made a significant impact on the transport, oil and software sectors.

Growth from banks and oil companies offset by falling mining dividends

The sharp decline in mining sector payouts globally, driven down one fifth by lower commodity prices, was almost exactly offset in Q1 by the strong positive contribution to growth from banks and oil companies. Most sectors delivered single-digit growth and there were relatively few weak spots. Globally, 95% of companies either raised dividends or held them steady in Q1.

Janus Henderson now expects total dividends for 2023 of $1.64 trillion¹ globally, equivalent to a headline increase of 5.2% for the year and underlying growth of 5.0%².

Ben Lofthouse, head of global equity income at Janus Henderson said: “Q1’s strong dividend growth is all the more impressive considering that 2022 was a difficult year for the global economy with high inflation, rising interest rates, conflict and continuing Covid lock downs. This growth illustrates the fact that dividends are generally less volatile than earnings. We do expect dividend growth to slow as a result of these factors but should nevertheless continue in line with the long-term trend this year.”

To receive a copy of the latest Janus Henderson Global Dividend Index, click here.

______________

¹ Up from $1.60 trillion in January

² Up from 3.4% in January

Notes to editors

Our headline growth rate describes the change in the total dollar amount paid by companies compared to the corresponding quarter each year. Our underlying figure adjusts for the distortion that can be caused by one-off special dividends, changing exchange rates, the effect of companies entering and leaving the global top 1,200 that comprise our index and the impact of changes in payment dates. The latter two tend to be negligible over the course of a whole year at the global level, though they can have a greater impact in any one quarter, geography or sector.

About Janus Henderson

Janus Henderson Group is a leading global active asset manager dedicated to helping investors achieve long-term financial goals through a broad range of investment solutions, including equities, fixed income, multi-asset, and alternative asset class strategies.

At 31 March 2023, Janus Henderson had approximately US$311 billion in assets under management, more than 2,000 employees, and offices in 24 cities worldwide. Headquartered in London, the company is listed on the NYSE and the ASX.

Source: Janus Henderson Global Dividend Index & Factset, April 2023

References made to individual securities do not constitute a recommendation to buy, sell or hold any security, investment strategy or market sector, and should not be assumed to be profitable. Janus Henderson Investors, its affiliated advisor, or its employees, may have a position in the securities mentioned.

This press release is solely for the use of members of the media and should not be relied upon by personal investors, financial advisers or institutional investors. We may record telephone calls for our mutual protection, to improve customer service and for regulatory record keeping purposes. All opinions and estimates in this information are subject to change without notice

Issued by Janus Henderson Investors. Janus Henderson Investors is the name under which investment products and services are provided by Janus Henderson Investors International Limited (reg no. 3594615), Janus Henderson Investors UK Limited (reg. no. 906355), Janus Henderson Fund Management UK Limited (reg. no. 2678531), Henderson Equity Partners Limited (reg. no. 2606646), (each registered in England and Wales at 201 Bishopsgate, London EC2M 3AE and regulated by the Financial Conduct Authority) and Janus Henderson Investors Europe S.A. (reg no. B22848 at 2 Rue de Bitbourg, L-1273, Luxembourg and regulated by the Commission de Surveillance du Secteur Financier). Henderson Secretarial Services Limited (incorporated and registered in England and Wales, registered no. 1471624, registered office 201 Bishopsgate, London EC2M 3AE) is the name under which company secretarial services are provided. All these companies are wholly owned subsidiaries of Janus Henderson Group plc. (incorporated and registered in Jersey, registered no. 101484, with registered office at 13 Castle Street, St Helier, Jersey, JE1 1ES). Janus Henderson Investors (Australia) Limited ABN 47 124 279 518 is not under any obligation to update this information to the extent that it is or becomes out of date or incorrect.

Janus Henderson, Knowledge Shared and Knowledge Labs are trademarks of Janus Henderson Group plc or one of its subsidiaries. © Janus Henderson Group plc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230524005263/en/

Press Enquiries

Janus Henderson Investors

Sarah Johnson

Director, Media Relations & Corp Comms

+1 (720) 364 0708

[email protected]

KEYWORDS: United States North America Colorado

INDUSTRY KEYWORDS: Asset Management Professional Services Finance

MEDIA:

Logo

Confidence Among Small to Midsize Businesses Waning Amid Economic Downturn

The CBIZ Main Street Index reveals rising borrowing costs, sticky inflation and staff retention as the most prevalent challenges facing SMBs ahead of likely recession

CLEVELAND–(BUSINESS WIRE)–CBIZ, Inc. (NYSE: CBZ), a leading provider of financial, insurance and advisory services, has released the results of its Q2 2023 Main Street Index, taking the pulse of and gauging the outlook for small and midsize businesses (SMBs) amid the current economic downturn. The results show contractions in all facets of business sentiment, most notably revenue and access to credit. The responses brought the index’s Business Confidence Study, a weighted average of SMB confidence-focused questions, down from 68 points last quarter to just above 60 points.

The index depicts a sharp rise in business owners who are concerned about retaining their full staff over the next quarter, as layoffs persist despite relatively strong month-over-month hiring data. Almost half of respondents (48%) listed employee retention as a top concern, up 25% from Q1. Retaining employee headcount trailed worries about a recession (62%) and having enough skilled workers on staff (56%) as the most common concerns, with layoffs across many sectors continuing due to tightening credit conditions and inflation remaining stubbornly high.

“There’s a lagging effect to last year’s interest rate hikes,” said Anna Rathbun, chief investment officer of CBIZ Investment Advisory Services. “The latest CBIZ Main Street Index shows the Fed’s actions, along with other factors, are starting to open more cracks in the foundation of the economy. A recession is like a zero-sum game. There will be winners and losers. We’re going to be keeping a close eye on the small and midsize businesses that are poised to do well during the downturn. The coming months will test the durability and savviness of business owners, especially those in industries that are not recession-proof.”

Based on a survey conducted between April 24 and May 5, the index analyzed responses from 753 businesses with fewer than 100 employees in 31 industries across the U.S.* The index assesses a range of timely trends, including business sentiment, areas of growth and decline, and price changes due to inflation and inventory levels.

The data was evaluated from an overall perspective, as well as based on company size, region and industry. An interactive infographic with the results is available on the CBIZ website. Key findings include:

• 51% of respondents have a negative or neutral outlook on the economy: As multiple economic indicators point to a slowing economy, the index revealed that only 49% of respondents reported positive or very positive business confidence over the next six months. Additionally, more than seven in 10 expected a further downturn in the economy, on par with last quarter’s survey.
• Sharp rise in concerns about employee retention amid unsettled labor market: A rising number of businesses are concerned about retaining employees amid a labor market that is experiencing steady hiring but also layoffs across many sectors. More than 48% of respondents listed employee retention as one of their key concerns this quarter.
• Over 75% of companies raised prices of goods and services in the last quarter: More than three in four businesses reported price increases by at least 1% over the past three months, up from 72% in Q1, due to high inflation remaining persistent, low inventory levels or other factors. Additionally, more than 55% of businesses said they’ve raised prices by 5% or more.
• Rising interest rates are having a greater impact on business funding: Twenty-seven percent of respondents said higher interest rates have impacted the funding needs of their businesses, up from 17% in the first quarter. Meanwhile, 64% of companies reported experiencing higher borrowing costs, a figure that remains unchanged from last quarter.

*Note: Not all those surveyed in the CBIZ Main Street Index are clients of CBIZ.

About CBIZ

CBIZ, Inc. provides professional business services that help clients better manage their finances and employees. CBIZ provides its clients with financial services, including accounting, tax, financial advisory, government health care consulting, risk advisory, real estate consulting and valuation services. Employee services include employee benefits consulting, property and casualty insurance, retirement plan consulting, payroll, life insurance, HR consulting and executive recruitment. As one of the largest accounting, insurance brokerage and valuation companies in the United States, the Company’s services are provided through more than 120 Company offices in 33 states. For more information, visit www.cbiz.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230524005199/en/

Media

Rocco Aloe

Gregory FCA for CBIZ, Inc.

[email protected]

610-860-2075

KEYWORDS: United States North America Ohio

INDUSTRY KEYWORDS: Consulting Professional Services Small Business Insurance Human Resources

MEDIA:

Logo

RenovoRx to Present at the LD Micro Invitational XIII Conference

LOS ALTOS, Calif.–(BUSINESS WIRE)–RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of cancers, today announced that Shaun Bagai, CEO, will present at the 13th Annual LD Micro Invitational, held on June 6-8, 2023 at the Luxe Sunset Boulevard Hotel in Los Angeles, California.

Mr. Bagai will provide a corporate update including recently announced positive interim data for the Company’s ongoing open label, randomized Phase III TIGeR-PaC clinical trial to treat Locally Advanced Pancreatic Cancer (LAPC). Interim data demonstrated that patients on the RenovoGem™ test arm demonstrated a 60% survival benefit and 65% side effect reduction versus systemic chemotherapy.

Presentation Details:

Date: Tuesday, June 6, 2023

Time: 1:00 p.m. – 1:25 p.m. PT

Registration/Webcast Link: https://ldinv13.sequireevents.com/

For more information about the conference, or to schedule a one-on-one meeting with RenovoRx’s management team, please contact your appropriate LD Micro representatives, or email [email protected].

A webcast of the event will be available for a limited time on the Events page in the Investors section of the Company’s website.

About RenovoGem

RenovoGem™ is the first drug-device combination product candidate that utilizes the RenovoTAMP^® therapy platform via pressure-mediated delivery technology to deliver gemcitabine, an FDA-approved systemic chemotherapy, locally across the arterial wall to bathe tumor tissue in the chemotherapy. RenovoGem is currently being evaluated in the Phase III TIGeR-PaC clinical trial study in Locally Advanced Pancreatic Cancer (LAPC) patients. The Company plans to investigate RenovoGem in extrahepatic Cholangiocarcinoma (eCCA) in a clinical trial, which is anticipated to begin in the first half of 2023. RenovoGem™ is currently under investigation for the intra-arterial delivery of gemcitabine and has not been approved for commercial sale.

About RenovoRx, Inc.

RenovoRx is a clinical-stage biopharmaceutical company with a vision to disrupt the current paradigm of cancer treatment. Our mission is to lead a revolution in oncology therapy by delivering its innovative and targeted intra-arterial (IA) delivery of chemotherapy directly to solid tumors. The proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP^®) therapy platform aims to avoid the harsh side effects typical of the current standard of care, or systemic delivery methods, thus improving patient well-being and, potentially extension of life, so more time may be enjoyed with loved ones. RenovoTAMP utilizes approved chemotherapeutics with validated mechanisms of action and well-established safety and clinical use, with the goal of improving their safety, tolerance, and widening their therapeutic window by providing more targeted delivery at the location of the tumor tissue. RenovoRx’s lead product candidate, RenovoGem™, is a combination of gemcitabine and its patented delivery system, RenovoCath^®, and is regulated by the FDA as a novel oncology drug product to treat unresectable locally advanced pancreatic cancer (LAPC). RenovoGem is currently being studied in the Phase III TIGeR-PaC clinical trial for the treatment of LAPC.

RenovoRx’s patent portfolio for its therapy platform and product candidates includes eight issued U.S. patents, one issued European patent, and several additional patents pending in the US, EU and Asia. RenovoRx has been granted Orphan Drug Designation for intra-arterial delivery of gemcitabine for the treatment of both pancreatic cancer and bile duct cancer (cholangiocarcinoma).

Learn more by visiting the RenovoRx website or following RenovoRx on Facebook, LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230524005310/en/

Investor Contact:

KCSA Strategic Communications

Valter Pinto or Jack Perkins

T:212-896-1254

[email protected]

Media Contact:

Kimberly Ha

T: 9172915744

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Biotechnology Health Pharmaceutical Clinical Trials Oncology

MEDIA:

Posted on May 24, 2023 9:54 am

Belden Launches Solutions to Enable Device Commissioning and Provide Advanced Cybersecurity

Belden Launches Solutions to Enable Device Commissioning and Provide Advanced Cybersecurity

Releases include additions to Belden’s PROVIZE Network Planning, Commissioning and Management Suite; a new Hirschmann Firewall; and a 4-Channel SMPTE Cable and VFD Cable Glands from Belden

ST. LOUIS–(BUSINESS WIRE)–
Belden Inc. (NYSE: BDC), a leading global supplier of network infrastructure and digitization solutions, announces five new products that provide enhanced security, better performance and seamless integration.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230524005041/en/

Belden Launches Solutions to Enable Device Commissioning and Provide Advanced Cybersecurity (Graphic: Business Wire)

Data Orchestration & Management

• Belden PROVIZE Explorer enables device commissioning by assigning management IP addresses and credentials via an easy-to-use interface. As part of Belden’s PROVIZE Suite, PROVIZE Explorer integrates seamlessly with network planning and management applications.
• Belden PROVIZE Planner allows users to gather requirements, build and validate intent-based networks and automatically create and export bills of materials listing recommended equipment via a single, easy-to-use interface. As part of Belden’s PROVIZE Suite, PROVIZE Planner integrates seamlessly with exploration and management applications.
• Hirschmann EAGLE40-4F firewalls provide deep packet inspection and advanced cybersecurity along with real-time traffic monitoring—all at an optimal price-to-performance ratio. With a robust design and varied certifications, the Hirschmann EAGLE40-4F is optimal for many industrial applications.

Data Acquisition & Transmission

• Belden 4-Channel SMPTE Cable is a multi-channel hybrid cable that allows four cameras to be connected to a single installed cable. The 4-Channel SMPTE is available in riser and plenum versions, features a black outer jacket and is backed by Belden’s industry-leading standard 10-year warranty.
• Belden VFD Cable Glands allow explosion-proof or general-purpose ingress of VFD cables into enclosures and devices. Featuring a pass-through design for shield/ground isolation, VFD Cable Glands are ideal for all types of unarmored tray cables, flexible cables and cords—even in the most demanding industrial environments.

To learn more about these solutions, as well as the types of technologies and applications they support, visit www.belden.com/new-products.

About Belden

Belden Inc. delivers the infrastructure that makes the digital journey simpler, smarter and secure. We’re moving beyond connectivity—from what we make to what we make possible through a performance-driven portfolio, forward-thinking expertise and purpose-built solutions. With a legacy of quality and reliability spanning 120-plus years, we have a strong foundation to continue building the future. We are headquartered in St. Louis and have manufacturing capabilities in North America, Europe, Asia and Africa. For more information, visit us at www.belden.com; follow us on Facebook, LinkedIn and Twitter.

Belden and the Belden logo and Hirschmann are trademarks or registered trademarks of Belden Inc. or its affiliated companies in the United States and other jurisdictions. Belden and other parties may also have trademark rights in other terms used herein.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230524005041/en/

Lisa Williams

Marketing Communications Manager

(317) 815-2402

[email protected]

Scott Todd

Marketing Communications Manager

(317) 316-6473

[email protected]

KEYWORDS: United States North America Missouri

INDUSTRY KEYWORDS: Data Management Security Technology Audio/Video Software Networks Hardware

MEDIA:

Logo

Photo

Belden Launches Solutions to Enable Device Commissioning and Provide Advanced Cybersecurity (Graphic: Business Wire)